🔎 Trials Near Me

መነሻ › አኩት ማይሎይድ ሊውኬሚያ › Ohio › Columbus

በColumbus፣ OH ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 35 ጥናቶች በColumbus እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 60 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • The Mark H Zangmeister Center, Columbus
  • እና 8 ተጨማሪ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05564390

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT03874052

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Nationwide Children's Hospital, Columbus
6 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Ohio State University, Columbus
30 Days · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT04065399

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Ohio State University, The James Comprehensive Cancer, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06846606

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • The Ohio Sate University, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06969430

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT04049539

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • OhioHealth Research Institute, Columbus
እድሜ 0 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • US-Colombus OH-OSU, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • US-Colombus OH-OSU, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT07223814

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ27 ኦገስ 2026 · NCT06930352

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Ohio State University, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT06533761

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Nationwide Children's Hospital, Columbus
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Nationwide Children's Hospital, Columbus
29 Days – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Ohio State University, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07007312

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Nationwide Children's Hospital, Columbus
  • The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ጁን 2026 · NCT05401097

Ivosidenib as Post-HSCT Maintenance for AML

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ18 ጁን 2026 · NCT06707493

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሜይ 2026 · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The Ohio State University, Columbus
እድሜ 13 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኤፕሪ 2026 · NCT04256317

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Ohio State University Medical Center, Columbus
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ25 ማርች 2026 · NCT03533816

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • The Ohio State University Comprehensive Cancer Center, Columbus
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ማርች 2026 · NCT04988555

Ziftomenib Maintenance Post Allo-HCT

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ማርች 2026 · NCT06440135

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The James Cancer Hospital and Solove Research Institute, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2025 · NCT06501196

HPC Offered for PRESERVE Expansion

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • The Ohio State University Medical Center, Columbus
እድሜ ከ12 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2025 · NCT07145411

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • The Ohio State University Wexner Medical Center, Columbus
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
  • Ohio State University, Columbus
እድሜ ከ18 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ25 ጁላይ 2025 · NCT05237258

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Nationwide Children's Hospital, Columbus
እድሜ ከ1 እስከ 24 · ሁሉም ጾታዎች · የተሻሻለው በ4 ኖቬም 2024 · NCT05503134

በሌሎች ከተሞች ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ጥናቶች

በColumbus ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።